The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Stiripentol: Efficacy and Tolerability in Children with Epilepsy
Abstract
Summary: Purpose: Stiripentol (STP) is a new antiepileptic drug (AED) that inhibits cytochrome P 450′ resulting in increased plasma concentrations of concomitant AEDs. The efficacy and tolerability of STP as an add‐on therapy in children were assessed. Methods: Two hundred twelve patients with refractory epilepsy, aged from 1 month to 20.5 years, received STP either in a single‐blind, placebo‐controlled trial (108 patients) or in a further open trial (104 other patients selected by epilepsy syndrome for possible efficacy based on the results of the previous trial). Results: Among the 97 patients who could be analyzed for efficacy in the placebo‐controlled study, the median seizure frequency was lower at 3 months with STP than with the placebo (p > 0.0001); 49% responded to the drug, including 10% who became seizure free. Patients with partial epilepsy had the highest response rate (57%). Results were confirmed in the open study where 68% of the 91 patients receiving STP responded at 3 months. These patients were mainly those with partial epilepsy (73%) who were receiving carbamazepine (CBZ) (75%) as comedication (p > 0.001). Ten of the 20 children with severe myoclonic epilepsy in infancy also responded with clobazam (CLB) as comedication. Efficacy was sustained long term in 74% of the 94 patients still receiving STP at a mean 30‐month follow‐up. Adverse events were reported in 48% of the 212 patients, mainly anorexia and loss of weight, but these events required STP discontinuation in only nine cases. Side effects were minimized in the open trial by optimizing the dose of comedication. Conclusions: STP seems to be a promising add‐on drug, particularly when combined with CBZ in patients with partial childhood epilepsy refractory to vigabatrin (VGB) and with CLB in patients with severe myoclonic epilepsy in infancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stiripentol was more effective, in association with clobazam, in individuals with Dravet syndrome 194 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [194]
Citations
Cites
Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467
Self-citationMigrating Partial Seizures in Infancy: A Malignant Disorder with Developmental Arrest
Coppola, G., Plouin, P., Chiron, C., Robain, O., & Dulac, O. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb00961.x · Cited by 291
Self-citationSurvey of Seizure Disorders in the French Southwest. I. Incidence of Epileptic Syndromes
Loiseau, J., Loiseau, P., Guyot, M., Duché, B., Dartigues, J., & Aublet‐Cuvelier, B. (1990) · Epilepsia · doi:10.1111/j.1528-1157.1990.tb05493.x · Cited by 194
Severe myoclonic epilepsy in infants
Dravet, C. (1992) · Medical Entomology and Zoology · Cited by 184
Mechanisms of Idiosyncratic Hypersensitivity Reactions to Antiepileptic Drugs
Leeder, J. S. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01679.x · Cited by 158
Vigabatrin in the Treatment of Childhood Epilepsies: A Single‐Blind Placebo‐Controlled Study
Luna, D., Dulac, O., Pajot, N., & Beaumont, D. (1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05322.x · Cited by 123
Self-citationVigabatrin in Childhood Epilepsy
Dulac, O., Chiron, C., Luna, D., Cusmai, R., Pajot, N., Beaumont, D., & Mondragon, S. (1991) · Journal of Child Neurology · doi:10.1177/0883073891006002071 · Cited by 112
Self-citationAnticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro
Gerson, W., Fine, D., Sp, S., & Sensenbrenner, L. (1983) · Blood · doi:10.1182/blood.v61.5.889.889 · Cited by 103
Stiripentol kinetics in epilepsy: Nonlinearity and interactions
Levy, R. H., Loiseau, P., Guyot, M., Bléhaut, H., Tor, J., & Moreland, T. A. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.237 · Cited by 99
Kerr, B. M., Rettie, A. E., Eddy, A. C., Loiseau, P., Guyot, M., Wilensky, A. J., & Levy, R. H. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.110 · Cited by 92
Research works printed but not linked: 14
- Astoin J, 1978, Action de nouveaux alcools alpha‐ethyléniques sur le système nerveux central, Eur J Chem Chim Ther, 13, 41
- Micheletti G, 1988, Effect of stiripentol on petit mal‐like epilepsy in Wistar rat, Epilepsia, 29, 709
- Martinez‐Lage JM, 1984, Clinical antiepileptic efficacy of stiripentol in resistant partial epilepsies, Epilepsia, 25, 673
- Loiseau P, 1990, Randomized double‐blind, parallel, multicenter trial of stiripentol added to CBZ in the treatment of CBZ resistant epilepsies: an interim analysis, Epilepsia, 31, 618
- Renard F, 1993, Single‐blind add‐on trial of stiripentol in epileptic children, Epilepsia, 34, S74
- Dravet C, 1992, Epileptic syndromes in infancy, children and adolescence 2nd ed, 75
- Loiseau P, 1995, Potential antiepileptic drugs, 1045
- Levy RH, 1985, Stiripentol concentration‐dose relationship and interaction with CBZ in epileptic patients, Epilepsia, 26, 544
- Loiseau P, 1987, Stiripentol in absence seizures: an open study, Epilepsia, 28, 579
- Loiseau P, 1989, Stiripentol in absence seizures: an open study updated, Epilepsia, 30, 639
- Farwell JA, 1992, Stiripentol shows promise in partial complex seizures in children, Epilepsia, 33, S81
- Chiron C, 1993, Multifocal epilepsy in infancy: value of stiripentol‐clonazepam combination, Epilepsia, 34, 73
- Levy RH, 1987, Effect of stiripentol on valproate plasma concentration and metabolism, Epilepsia, 28, 605
- Elterman R, 1997, Topiramate YP study team: a double‐blind trial of topiramate in partial seizures in children, Epilepsia, 38, 131
Cited by
Sorted by citations
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H. ‐., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K. M., Gerlach, M., Greiner, C., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,494
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K. M., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 871
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568
Self-citationProgress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.07.010 · Cited by 300
Löscher, W., & Schmidt, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00607.x · Cited by 239
Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome
Griffin, A., Hamling, K. R., Knupp, K. G., Hong, S., Lee, L. P., & Baraban, S. C. (2016) · Brain · doi:10.1093/brain/aww342 · Cited by 228
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 158
The pharmacologic treatment of Dravet syndrome
Chiron, C., & Dulac, O. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03007.x · Cited by 151
Self-citationQuilichini, P., Chiron, C., Ben‐Ari, Y., & GOZLAN, H. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00497.x · Cited by 147
Self-citationIN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISM
Giraud, C., Tréluyer, J., Rey, E., Chiron, C., Vincent, J., Pons, G., & Tran, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007237 · Cited by 131
Self-citationDevelopmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
Malignant migrating partial seizures in infancy: An epilepsy syndrome of unknown etiology
Coppola, G. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02121.x · Cited by 114
Zhang, Y., Kecskés, A., Copmans, D., Langlois, M., Crawford, A. D., Ceulemans, B., Lagae, L. G., de Witte, P. A. M., & Esguerra, C. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125898 · Cited by 112
Dravet syndrome: Treatment options and management of prolonged seizures
Cross, J. H., Caraballo, R. H., Nabbout, R., Vigevano, F., Guerrini, R., & Lagae, L. G. (2019) · Epilepsia · doi:10.1111/epi.16334 · Cited by 117
The Long-Term Safety of Antiepileptic Drugs
Gaitatzis, A., & Sander, J. W. A. S. (2013) · CNS Drugs · doi:10.1007/s40263-013-0063-0 · Cited by 108
Ishii, A., Shioda, M., Okumura, A., Kidokoro, H., Sakauchi, M., Shimada, S., Shimizu, T., Ōsawa, M., Hirose, S., & Yamamoto, T. (2013) · Gene · doi:10.1016/j.gene.2013.08.096 · Cited by 101
Chiron, C. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.10.001 · Cited by 98
Self-citationGuerrini, R., & Aicardi, J. F. (2003) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200311000-00007 · Cited by 92
Recent Advances in the Drug Treatment of Dravet Syndrome
Wirrell, E. C., & Nabbout, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00666-8 · Cited by 92
Thanh, T. N., Chiron, C., Dellatolas, G., Rey, E., Pons, G., Vincent, J., & Dulac, O. (2002) · Archives de Pédiatrie · doi:10.1016/s0929-693x(02)00090-8 · Cited by 84
Self-citationPharmacological Management of Epilepsy
Landmark, C. J., & Johannessen, S. I. (2008) · Drugs · doi:10.2165/00003495-200868140-00001 · Cited by 63
Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases
Vendrame, M., Poduri, A., Loddenkemper, T., Kluger, G. J., Coppola, G., & Kothare, S. V. (2011) · Epileptic Disorders · doi:10.1684/epd.2011.0406 · Cited by 62
Treatment Strategies for Dravet Syndrome
Knupp, K. G., & Wirrell, E. C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0511-y · Cited by 65
Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam
Merdariu, D., Delanöe, C., Mahfoufi, N., Bellavoine, V., & Auvin, S. (2012) · Brain and Development · doi:10.1016/j.braindev.2012.03.016 · Cited by 59
Novel de novo SCN2A Mutation in a Child With Migrating Focal Seizures of Infancy
Dhamija, R., Wirrell, E., Falcao, G., Kirmani, S., & Wong-Kisiel, L. C. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.07.004 · Cited by 59
Severe Myoclonic Epilepsy in Infancy: Toward an Optimal Treatment
Ceulemans, B., Boel, M., Claes, L. R. F., Dom, L., Willekens, H., Thiry, P., & Lagae, L. G. (2004) · Journal of Child Neurology · doi:10.1177/08830738040190070701 · Cited by 59
Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy
Guerrini, R., Zaccara, G., la Marca, G., & Rosati, A. (2012) · Drug Safety · doi:10.2165/11630700-000000000-00000 · Cited by 56
Synergistic GABA-Enhancing Therapy against Seizures in a Mouse Model of Dravet Syndrome
Oakley, J. C., Cho, A. R., Cheah, C. S., Scheuer, T., & Catterall, W. A. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203331 · Cited by 56
Current therapeutic procedures in Dravet syndrome
Chiron, C. (2011) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2011.03967.x · Cited by 55
Self-citationDo children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
Chiron, C., Hélias, M., Kamińska, A., Laroche, C., de Toffol, B., Dulac, O., Nabbout, R., & Gourfinkel‐An, I. (2018) · Epilepsia · doi:10.1111/epi.14536 · Cited by 55
Self-citationChiron, C., Tonnelier, S., Rey, E., Brunet, M.-L., Tran, A., d’Athis, P., Vincent, J., Dulac, O., & Pons, G. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210062101 · Cited by 55
Self-citationConcentrations of Stiripentol in Children and Adults With Epilepsy
May, T. W., Boor, R., Mayer, T., Jürgens, U. H., Rambeck, B., Holert, N., Korn‐Merker, E., & Brandt, C. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31825dc4a6 · Cited by 54
Djurić, M., Kravljanac, R., Kovacevic, G. S., & Martić, J. (2011) · Epileptic Disorders · doi:10.1684/epd.2011.0402 · Cited by 53
Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human
Cazali, N., Tran, A., Tréluyer, J., Rey, E., d’Athis, P., Vincent, J., & Pons, G. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01919.x · Cited by 53
Self-citationEfficacy of stiripentol in hyperthermia‐induced seizures in a mouse model of Dravet syndrome
Cao, D., Ohtani, H., Ogiwara, I., Ohtani, S., Takahashi, Y., Yamakawa, K., & Inoue, Y. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03497.x · Cited by 52
Stiripentol: A Review in Dravet Syndrome
Frampton, J. E. (2019) · Drugs · doi:10.1007/s40265-019-01204-y · Cited by 52
Interactions between modulators of the GABAA receptor: Stiripentol and benzodiazepines
Fisher, J. L. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.037 · Cited by 51
Stiripentol. A novel antiepileptic drug.
Trojnar, M. K., Wojtal, K., Trojnar, M. P., & Czuczwar, S. J. (2005) · PubMed · Cited by 51
Stiripentol in the Management of Epilepsy
Nickels, K. C., & Wirrell, E. C. (2017) · CNS Drugs · doi:10.1007/s40263-017-0432-1 · Cited by 51
Landmark, C. J., Potschka, H., Auvin, S., Wilmshurst, J. M., Johannessen, S. I., Trenité, D. G. A. K.-N., & Wirrell, E. C. (2021) · Epilepsia · doi:10.1111/epi.16849 · Cited by 49
Treatment Strategies for Myoclonic Seizures and Epilepsy Syndromes with Myoclonic Seizures
Wheless, J. W., & Sankar, R. (2003) · Epilepsia · doi:10.1046/j.1528-1157.44.s11.5.x · Cited by 46
Chiron, C. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.7.905 · Cited by 45
Self-citationAn Update on Stiripentol Mechanisms of Action: A Narrative Review
Bacq, A., Depaulis, A., Castagné, V., Guern, M. L., Wirrell, E. C., & Verleye, M. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02813-0 · Cited by 43
Treatment of epilepsy existing therapies and future developments
Aiken, S. P. (2000) · Frontiers in bioscience · doi:10.2741/aiken · Cited by 43
Diagnosis and Management of Epileptic Encephalopathies in Children
Jain, P., Sharma, S., & Tripathi, M. (2013) · Epilepsy Research and Treatment · doi:10.1155/2013/501981 · Cited by 42
Łuszczki, J. J., & Czuczwar, S. J. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0100-3 · Cited by 41
Changing Landscape of Dravet Syndrome Management: An Overview
Samanta, D. (2020) · Neuropediatrics · doi:10.1055/s-0040-1701694 · Cited by 42
Malignant migrating partial seizures in infancy
Coppola, G. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52891-9.00062-2 · Cited by 37
Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy
Moavero, R., Pisani, L. R., Pisani, F., & Curatolo, P. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1518427 · Cited by 37
Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain
Auvin, S., Lecointe, C., Dupuis, N., Desnous, B., Lebon, S., Gressèns, P., & Dournaud, P. (2013) · Epilepsia · doi:10.1111/epi.12401 · Cited by 37
A selective NaV1.1 activator with potential for treatment of Dravet syndrome epilepsy
Chow, C. Y., Chin, Y. K. ‐., Ma, L., Undheim, E. A. B., Herzig, V., & King, G. F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113991 · Cited by 36
Dravet syndrome: From electroclinical characteristics to molecular biology
Arzimanoglou, A. A. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02228.x · Cited by 35
Impact of Antiseizure Medications on Appetite and Weight in Children
Buraniqi, E., Dabaja, H., & Wirrell, E. C. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00505-2 · Cited by 33
Sills, G. J. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231191000 · Cited by 30
Łuszczki, J. J., Trojnar, M. K., Ratnaraj, N., Patsalos, P. N., & Czuczwar, S. J. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.04.006 · Cited by 30
Venom-derived modulators of epilepsy-related ion channels
Chow, C. Y., Absalom, N. L., Biggs, K. A., King, G. F., & Ma, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114043 · Cited by 28
Peigné, S., Chhun, S., Tod, M. M., Rey, E., Rodrigues, C., Chiron, C., Pons, G., & Jullien, V. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0592-7 · Cited by 28
Self-citationBalestrini, S., Doccini, V., Boncristiano, A., Lenge, M., MASI, S. D., & Guerrini, R. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00305-7 · Cited by 26
Łuszczki, J. J., Ratnaraj, N., Patsalos, P. N., & Czuczwar, S. J. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00825.x · Cited by 26
Stiripentol for the treatment of seizures associated with Dravet syndrome
Chiron, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1593142 · Cited by 27
Self-citationInnovations in Epilepsy Management – An Overview
Abraham, S., & Shaju, M. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j32k5b · Cited by 25
Future Prospects for the Drug Treatment of Epilepsy
Nicolson, A., & Leach, J. P. (2001) · CNS Drugs · doi:10.2165/00023210-200115120-00005 · Cited by 25
Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine
Ali, Q. Z., Marques, P., Selvarajah, A., Tabarestani, S., Sadoway, T. R., & Andrade, D. M. (2020) · Epilepsia · doi:10.1111/epi.16684 · Cited by 24
Welty, T. E. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608050-00003 · Cited by 24
Jogamoto, T., Yamamoto, Y., Fukuda, M., Suzuki, Y., Imai, K., Takahashi, Y., Inoue, Y., & Ohtsuka, Y. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.12.014 · Cited by 23
Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions
Auvin, S., Avberšek, A., Bast, T., Chiron, C., Guerrini, R., Kaminski, R. M., Lagae, L. G., Muglia, P., & Cross, J. H. (2019) · Drugs · doi:10.1007/s40265-019-01223-9 · Cited by 23
Self-citationAntiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
Brigo, F., & Igwe, S. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010483.pub3 · Cited by 23
Plosker, G. L. (2012) · CNS Drugs · doi:10.1007/s40263-012-0004-3 · Cited by 22
Pharmacological considerations in the use of stiripentol for the treatment of epilepsy
Verrotti, A., Prezioso, G., Stagi, S., Paolino, M. C., & Parisi, P. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1145657 · Cited by 22
Stiripentol: An example of antiepileptic drug development in childhood epilepsies
Nabbout, R., & Chiron, C. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.04.009 · Cited by 21
Self-citationExtending the use of stiripentol to other epileptic syndromes: A case of PCDH19-related epilepsy
Trivisano, M., Specchio, N., & Vigevano, F. (2014) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2014.11.008 · Cited by 21
Efficacy of Stiripentol in Dravet Syndrome with or without SCN1A Mutations
Cho, M. J., Kwon, S. S., Ko, A., Lee, S., Lee, Y., Kim, H. D., Chung, H. J., Kim, S. H., Lee, J. S., Kim, D., et al. (2018) · Journal of Clinical Neurology · doi:10.3988/jcn.2018.14.1.22 · Cited by 21
Hart, X. M., Gründer, G., Unterecker, S., Schoretsanitis, G., Hiemke, C., Adamovic, I., Amann, F., Baumann, P., Bergemann, N., Brandt, C., et al. (2026) · Pharmacopsychiatry · doi:10.1055/a-2860-7861 · Cited by 20
Gil‐Nagel, A., Aledo‐Serrano, Á., Beltrán‐Corbellini, Á., Martínez‐Vicente, L., Jiménez‐Huete, A., Toledano, R., Morales, I. G., & Carbó, A. V. (2023) · Epilepsia Open · doi:10.1002/epi4.12847 · Cited by 20
Guerrini, R., Chancharme, L., Serraz, B., & Chiron, C. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00623-8 · Cited by 19
Self-citationStiripentol for the treatment of seizures in Dravet syndrome
Eschbach, K. L., & Knupp, K. G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1605904 · Cited by 19
Rosati, A., Boncristiano, A., Doccini, V., Pugi, A., Pisano, T., Lenge, M., MASI, S. D., & Guerrini, R. (2019) · Epilepsia · doi:10.1111/epi.16363 · Cited by 19
Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy
Brigo, F., & Storti, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010483.pub2 · Cited by 19
Phenytoin administration in the newborn and infant
Sicca, F., Contaldo, A., Rey, E., & Dulac, O. (2000) · Brain and Development · doi:10.1016/s0387-7604(99)00110-2 · Cited by 18
Self-citationPrezioso, G., Chiarelli, F., & Matricardi, S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2216385 · Cited by 17
Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome
Kouga, T., Shimbo, H., Iai, M., Yamashita, S., Ishii, A., Ihara, Y., Hirose, S., Yamakawa, K., & Osaka, H. (2014) · Brain and Development · doi:10.1016/j.braindev.2014.04.003 · Cited by 17
Stiripentol and vigabatrin current roles in the treatment of epilepsy
Chiron, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1161026 · Cited by 17
Self-citationNew and emerging pharmacologic treatments for developmental and epileptic encephalopathies
Vasquez, A., Buraniqi, E., & Wirrell, E. C. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001029 · Cited by 16
Macleod, S., & Appleton, R. E. (2007) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2007.106880 · Cited by 16
Debotton, N., & Dahan, A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.014 · Cited by 15
Use of Stiripentol in Dravet Syndrome: A Guide for Clinicians
Wheless, J. W., & Weatherspoon, S. E. (2024) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2024.10.015 · Cited by 14
Vasquez, A., Wirrell, E. C., & Youssef, P. E. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2195550 · Cited by 14
A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children
and the CRESim & Epi-CRESim Project Groups, Ogungbenro, K., & Aarons, L. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1451-y · Cited by 14
Stiripentol for focal refractory epilepsy
Brigo, F., Storti, M., & Igwe, S. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009887.pub3 · Cited by 14
A Revisited Strategy for Antiepileptic Drug Development in Children
Chiron, C., Kassai, B., Dulac, O., Pons, G., & Nabbout, R. (2013) · CNS Drugs · doi:10.1007/s40263-012-0035-9 · Cited by 17
Self-citationDietary therapy is not the best option for refractory nonsurgical epilepsy
Vaccarezza, M. M., & Silva, W. H. (2015) · Epilepsia · doi:10.1111/epi.13074 · Cited by 12
Miziak, B., & Czuczwar, S. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1857722 · Cited by 12
Neurogenetic Disorders and Treatment of Associated Seizures
Faulkner, M. A., & Singh, S. P. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1201 · Cited by 12
Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy
Brigo, F., Storti, M., & Felice, A. D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010483 · Cited by 12
Stiripentol add-on therapy for focal refractory epilepsy
Brigo, F., Igwe, S. C., & Bragazzi, N. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009887.pub4 · Cited by 11
Child Neurology: Epilepsy of infancy with migrating focal seizures
Sharma, S., Sankhyan, N., Konanki, R., & Gulati, S. (2011) · Neurology · doi:10.1212/wnl.0b013e3182267b4f · Cited by 10
Pharmacologic Treatment of Intractable Epilepsy in Children: A Syndrome-Based Approach
Hussain, S. A., & Sankar, R. (2011) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2011.06.003 · Cited by 10
Migrating Focal Seizures During Infancy: A Case Report and Pathologic Study
Fasulo, L., Saucedo, S., Cáceres, L., Solís, S., & Caraballo, R. H. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2011.12.004 · Cited by 10
Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
Brigo, F., Igwe, S. C., & Bragazzi, N. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010483.pub4 · Cited by 10
Metadata
- Authors
- Perez, J., Chiron, C., Musial, C., Rey, E., Blehaut, H., D'Athis, P., Vincent, J., & Dulac, O.
- Affiliations
- Inserm (FR)
- Hôpital Saint-Vincent-de-Paul (FR)
- Corresponding author
- Chiron, C.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1999-11
- Volume
- 40
- Issue
- 11
- Pages
- 1618-1626
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2040934129
- Cited by
- 148
- References
- 33
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 9 · 2019: 12 · 2018: 5 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 15 · 2012: 10
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Epilepsia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- stiripentol, adjunctive antiepileptic therapy, cytochrome P450 inhibition, carbamazepine, clobazam, vigabatrin, Dravet syndrome, focal epilepsy, seizure frequency, adverse events, drug tolerability
- MeSH terms
- Adolescent, Adult, Age Factors, Anticonvulsants, Child, Child, Preschool, Dioxolanes, Drug Therapy, Combination, Epilepsy, Epilepsies, Partial, Epilepsies, Myoclonic, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Placebos, Single-Blind Method, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review